Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Pipeline Review, H1 2019
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) - Integrin beta-3 (β3) or CD61 is a protein that in humans is encoded by the ITGB3 gene. Integrin beta 3 is found along with the alpha IIb chain in platelets. It is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Activation of integrin alpha-IIb/beta-3 leads to platelet interaction through binding of soluble fibrinogen. This leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.
Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) pipeline Target constitutes close to 24 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 2, 1, 1 and 15 respectively. Similarly, the universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Cardiovascular, Metabolic Disorders, Dermatology, Gastrointestinal, Infectious Disease and Immunology which include indications Breast Cancer, Wet (Neovascular / Exudative) Macular Degeneration, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Diabetic Nephropathy, Glioblastoma Multiforme (GBM), Metastatic Melanoma, Pancreatic Cancer, Persistent Corneal Epithelial Defects, Wounds, Diabetic Macular Edema, Escherichia Coli Septicaemia, Ischemic Stroke, Liver Cancer, Lung Cancer, Malabsorption Syndrome, Melanoma, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Primary Sclerosing Cholangitis, Prostate Cancer, Rheumatoid Arthritis, Sepsis and Staphylococcus Aureus Septicaemia.
The latest report Integrin Beta 3 - Pipeline Review, H1 2019, outlays comprehensive information on the Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Integrin Beta 3 (Platelet Membrane Glycoprotein IIIa or CD61 or ITGB3) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Reasons to buy
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook